These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 9114824)
1. Current and investigational therapies used to alter the course of disease in multiple sclerosis. Miller A South Med J; 1997 Apr; 90(4):367-75. PubMed ID: 9114824 [TBL] [Abstract][Full Text] [Related]
2. Investigational drug therapies of treatment of multiple sclerosis. Panitch HS Mult Scler; 1996 Sep; 2(2):66-77. PubMed ID: 9345383 [TBL] [Abstract][Full Text] [Related]
3. Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B; Cohen JA Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526 [TBL] [Abstract][Full Text] [Related]
4. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Frohman EM; Racke M; van Den Noort S Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973 [No Abstract] [Full Text] [Related]
7. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
11. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Rudick RA Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808 [TBL] [Abstract][Full Text] [Related]
12. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region]. Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035 [TBL] [Abstract][Full Text] [Related]
13. Disease modifying treatment in multiple sclerosis. Fuller GN; Bone I J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780 [No Abstract] [Full Text] [Related]
14. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept]. Kornhuber ME; Zierz S Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792 [No Abstract] [Full Text] [Related]
15. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis]. Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126 [TBL] [Abstract][Full Text] [Related]
16. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
17. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659 [TBL] [Abstract][Full Text] [Related]
18. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. Amato MP Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547 [TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)]. Zavalishin IA; Zhuchenko TD; Peresedova AV Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]